35 results
8-K
EX-99.1
TYRA
Tyra Biosciences Inc
9 May 24
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
4:08pm
research and development expenses were $17.2 million compared to $10.4 million for the same period in 2023.
First quarter 2024 general … Months Ended
March 31,
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income
DEFA14A
TYRA
Tyra Biosciences Inc
7 May 24
Additional proxy soliciting materials
4:34pm
and Development and as Director of Research and Development. Prior to his work in biotechnology, he was a medical oncologist and cancer researcher … at Pfizer, Dr. Rothenberg served in various roles at Loxo Oncology, Inc. from August 2015 to January 2020, including as Vice President of Research
8-K
TYRA
Tyra Biosciences Inc
7 May 24
Departure of Directors or Certain Officers
4:29pm
of Research and Development and as Director of Research and Development. Prior to his work in biotechnology, he was a medical oncologist and cancer
PRE 14A
tkibke85retiw4kg
5 Apr 24
Preliminary proxy
4:20pm
8-K
EX-99.1
moe9561pfk6qm
19 Mar 24
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
4:05pm
8-K
EX-99.1
47jv3ne3vii13
7 Nov 23
Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
4:07pm
8-K
EX-99.1
ctq677i4677qkzqvdnk
10 Aug 23
Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights
4:21pm
8-K
EX-99.1
juv0paqz1gu6c
4 May 23
Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights
4:08pm
8-K
EX-99.1
9n2oq
3 Nov 22
Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights
4:16pm
S-3
fs7juhku5k4 d52vzr3
3 Oct 22
Shelf registration
4:05pm
S-3
EX-1.2
42va0yok 3p
3 Oct 22
Shelf registration
4:05pm